Medtronic has launched the Enlite Sensor, the newest and most advanced glucose sensor for continuous glucose monitoring (CGM), in more than 35 countries outside of the United States.
The new Enlite Sensor combines greater comfort with improved glucose sensor performance in both overall accuracy and detection of hypoglycemia. According the the company when the Enlite Sensor is used with the predictive alerts feature on Medtronic systems, diabetes patients have access to hypo detection rates up to 98%. This helps give early warning to people with diabetes so they can take action to prevent dangerous hypoglycemia, which is one of the major concerns of people living with diabetes.
Significant design improvements make the Enlite Sensor more comfortable and easier to use than the previous sensor. In a clinical study of Enlite Sensor, 85% of patients agreed that sensor insertion was pain free and 86% agreed that the Enlite insertion device was easy to use. The Enlite Sensor is a significantly smaller sensor compared to Medtronic’s previous product. The Enlite Sensor can be worn on the abdomen and buttocks and used for up to six days.
The Enlite Sensor received CE (Conformité Européenne) Mark approval in Paris, France and is being launched subject to other local approvals in more than 35 countries. Medtronic is working closely with the U.S. Food and Drug Administration on plans to commercialize the product in the United States. The Enlite Sensor is labeled for use with: MiniMed Paradigm® REAL?Time System, MiniMed Paradigm Veo™ System, Guardian® REAL?Time Continuous Glucose Monitoring System, and the iProTM2.